Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice. 2009

Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
Section on Behavioral Science and Genetics, Laboratory for Integrative Neuroscience, National Institute on Alcoholism and Alcohol Abuse, NIH Rockville, MD, USA. brigmanj@mail.nih.gov

Subchronic treatment with the psychotomimetic phencyclidine (PCP) has been proposed as a rodent model of the negative and cognitive/executive symptoms of schizophrenia. There has, however, been a paucity of studies on this model in mice, despite the growing use of the mouse as a subject in genetic and molecular studies of schizophrenia. In the present study, we evaluated the effects of subchronic PCP treatment (5 mg/kg twice daily x 7 days, followed by 7 days withdrawal) in C57BL/6J mice on (1) social behaviors using a sociability/social novelty-preference paradigm, and (2) pairwise visual discrimination and reversal learning using a touchscreen-based operant system. Results showed that mice subchronically treated with PCP made more visits to (but did not spend more time with) a social stimulus relative to an inanimate one, and made more visits and spent more time investigating a novel social stimulus over a familiar one. Subchronic PCP treatment did not significantly affect behavior in either the discrimination or reversal learning tasks. These data encourage further analysis of the potential utility of mouse subchronic PCP treatment for modeling the social withdrawal component of schizophrenia. They also indicate that the treatment regimen employed was insufficient to impair our measures of discrimination and reversal learning in the C57BL/6J strain. Further work will be needed to identify alternative methods (e.g., repeated cycles of subchronic PCP treatment, use of different mouse strains) that reliably produce discrimination and/or reversal impairment, as well as other cognitive/executive measures that are sensitive to chronic PCP treatment in mice.

UI MeSH Term Description Entries

Related Publications

Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
February 2012, Behavioural brain research,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
January 1982, Developmental psychobiology,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
November 2005, Behavioural pharmacology,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
September 1990, Pharmacology, biochemistry, and behavior,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
March 2006, Cognitive, affective & behavioral neuroscience,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
February 2003, Brain, behavior, and immunity,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
August 1976, Psychological reports,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
November 2006, Behavioural brain research,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
January 2013, Behavioural brain research,
Jonathan L Brigman, and Jessica Ihne, and Lisa M Saksida, and Timothy J Bussey, and Andrew Holmes
June 2013, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Copied contents to your clipboard!